Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Know Labs Inc. (KNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: KNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40
1 Year Target Price $40
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.09% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 822.26M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 1 | Beta 1.76 | 52 Weeks Range 0.33 - 13.02 | Updated Date 08/29/2025 |
52 Weeks Range 0.33 - 13.02 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-14 | When After Market | Estimate -2.4 | Actual -0.55 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -363.88% | Return on Equity (TTM) -1867.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 396811574 | Price to Sales(TTM) 15.57 |
Enterprise Value 396811574 | Price to Sales(TTM) 15.57 | ||
Enterprise Value to Revenue 17.32 | Enterprise Value to EBITDA -3.51 | Shares Outstanding 384233984 | Shares Floating 7190007 |
Shares Outstanding 384233984 | Shares Floating 7190007 | ||
Percent Insiders 3.78 | Percent Institutions 0.08 |
Upturn AI SWOT
Know Labs Inc.
Company Overview
History and Background
Know Labs Inc. was founded in 1998 (though the non-invasive glucose monitoring technology has been developed since 2011) and is focused on developing and commercializing Bio-RFIDu2122, a non-invasive technology platform for measuring blood glucose levels. Significant milestones include developing their radio frequency spectroscopic sensor and commencing clinical trials. The company has pivoted to primarily focus on non-invasive glucose monitoring.
Core Business Areas
- Bio-RFIDu2122 Technology: The core technology platform using radio frequencies to identify and measure substances non-invasively, currently focused on glucose monitoring.
- Non-invasive Glucose Monitoring: Development and commercialization of a device for non-invasive glucose monitoring utilizing Bio-RFIDu2122.
Leadership and Structure
Ron Erickson is the Chairman of the Board and Steve Kent is the CEO. The company has a board of directors and a management team focused on engineering, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Bio-RFIDu2122 Glucose Monitor (in development): A non-invasive glucose monitor using radio frequency spectroscopy. Currently undergoing clinical trials and not yet commercialized. No current market share or revenue. Competitors include Abbott (FreeStyle Libre), Dexcom (G6/G7), and Medtronic (Guardian).
Market Dynamics
Industry Overview
The glucose monitoring market is experiencing growth due to the increasing prevalence of diabetes and the demand for continuous and non-invasive monitoring solutions. There's a strong push for less invasive and easier to use continuous glucose monitors (CGMs).
Positioning
Know Labs is positioned as an innovator in non-invasive glucose monitoring with its Bio-RFIDu2122 technology. The company hopes their technology will be more comfortable and more affordable than current CGM options.
Total Addressable Market (TAM)
The global diabetes care devices market is projected to reach USD 38.3 billion by 2028. Know Labs is positioned to potentially capture a portion of this market if their product is successfully commercialized and adopted.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Potential for improved patient comfort and compliance
- Novel approach to glucose monitoring
Weaknesses
- Technology is still in development
- Lack of regulatory approval
- Limited financial resources compared to competitors
- No currently commercialized product
Opportunities
- Growing demand for non-invasive glucose monitoring
- Potential for partnerships with diabetes care companies
- Expansion into other diagnostic applications using Bio-RFIDu2122
Threats
- Competition from established glucose monitoring companies
- Regulatory hurdles and clinical trial risks
- Technological challenges in achieving accurate and reliable measurements
- Risk of failing to receive FDA approval.
Competitors and Market Share
Key Competitors
- Abbott (ABT)
- Dexcom (DXCM)
- Medtronic (MDT)
Competitive Landscape
Know Labs faces intense competition from established players with significant resources and existing market share. Know Labs' success depends on their ability to demonstrate the accuracy and reliability of their non-invasive technology and secure regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Limited historical revenue growth due to the pre-commercialization stage.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approval, and commercialization of their Bio-RFIDu2122 glucose monitor. Analyst estimates vary widely given the uncertainty.
Recent Initiatives: Focusing on clinical trials and seeking partnerships to accelerate development and commercialization.
Summary
Know Labs is a high-risk, high-reward company in the pre-revenue stage, betting on its Bio-RFIDu2122 technology to revolutionize glucose monitoring. Its future hinges on the success of clinical trials and securing regulatory approval. The company faces significant competition and requires continuous funding to sustain operations. If the technology is successful, this could be big; however, success is not yet guaranteed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Know Labs Inc. Investor Relations
- Company SEC Filings
- Market Research Reports on Diabetes Care Devices
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. The accuracy of future projections cannot be guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Know Labs Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2022-09-16 | CEO - | ||
Sector Technology | Industry Scientific & Technical Instruments | Full time employees 6 | Website https://www.knowlabs.co |
Full time employees 6 | Website https://www.knowlabs.co | ||
Know Labs, Inc., together with its subsidiaries, focuses on the development and commercialization of proprietary sensor technology by radio and microwave spectroscopy in the United States. The company involved in the identifying and measuring any material or analyte using electromagnetic energy to detect, record, identify, and measure the signature of said materials or analytes. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was incorporated in 1998 and is based in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.